Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.
about
Extreme Multidrug Resistant HIV-1 Protease with 20 Mutations Is Resistant to Novel Protease Inhibitors with P1′-Pyrrolidinone or P2-Tris-tetrahydrofuranJoint X-ray/Neutron Crystallographic Study of HIV-1 Protease with Clinical Inhibitor Amprenavir: Insights for Drug DesignStructures of Darunavir-Resistant HIV-1 Protease Mutant Reveal Atypical Binding of Darunavir to Wide Open FlapsA Conserved Hydrogen-Bonding Network of P2 bis-Tetrahydrofuran-Containing HIV-1 Protease Inhibitors (PIs) with a Protease Active-Site Amino Acid Backbone Aids in Their Activity against PI-Resistant HIVThermodynamic and structural analysis of HIV protease resistance to darunavir - analysis of heavily mutated patient-derived HIV-1 proteasesProbing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological EvaluationEffects of Hinge Region Natural Polymorphisms on Human Immunodeficiency Virus-1 Protease Structure, Dynamics and Drug-Pressure EvolutionDesign and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands.Organic carbamates in drug design and medicinal chemistryDesign of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation.Enantioselective Synthesis of Dioxatriquinane Structural Motifs for HIV-1 Protease Inhibitors Using a Cascade Radical CyclizationHighly resistant HIV-1 proteases and strategies for their inhibition.Discovery of HIV Type 1 Aspartic Protease Hit Compounds through Combined Computational Approaches.Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands.Conformational variation of an extreme drug resistant mutant of HIV protease.Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray StudiesStructure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studiesImproving Viral Protease Inhibitors to Counter Drug Resistance.A fission yeast cell-based system for multidrug resistant HIV-1 proteases.Decoding HIV resistance: from genotype to therapy.Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDSDesign of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex.Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.Room Temperature Neutron Crystallography of Drug Resistant HIV-1 Protease Uncovers Limitations of X-ray Structural Analysis at 100 K.Developing HIV-1 Protease Inhibitors through Stereospecific Reactions in Protein Crystals.Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.Straightforward and highly diastereoselective synthesis of 2,2-di-substituted perhydrofuro[2,3-b]pyran (and furan) derivatives promoted by BiCl3.Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir.Gelatinase inhibitors: a patent review (2011-2017).Rational Design of a Highly Potent and Selective Peptide Inhibitor of PACE4 by Salt Bridge Interaction with D160 at Position P3.Can we design drugs for HIV/AIDS that are less susceptible to resistance?Design of Highly Potent, Dual Acting and Central Nervous System Penetrating HIV-1 Protease Inhibitors with Excellent Potency against Multidrug-Resistant HIV-1 Variants.An enantioselective enzymatic desymmetrization route to hexahydro-4H-furopyranol, a high-affinity ligand for HIV-1 protease inhibitors.Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.Lewis Acid Mediated Cyclizations: Diastereoselective Synthesis of Six- to Eight-Membered Substituted Cyclic Ethers.HIV-Associated Neurocognitive Disorder (HAND) and the Prospect of Brain-Penetrating Protease Inhibitors for Antiretroviral Treatment.
P2860
Q27677405-BDD13644-CDBF-45C9-AC89-878F839A7EC5Q27678644-E64CA897-EA36-4BDA-8CFE-611D43AF5658Q27683434-EEAB0DAA-317F-4E90-8803-D35FF107739AQ27683486-B46C670C-8EFF-4891-BD14-489EEA3F1B54Q27690132-4B0B660D-3431-46B3-87E0-038BDDB14986Q27717366-D29ADAF2-FE28-40A7-B9CE-B3FD02B9077DQ27727967-A87F69F4-50BF-4DF3-B4BD-91F19568BDE8Q34046931-8AD6D8B0-F681-483F-AF23-1AA263741D49Q35365543-BF0ED736-330E-40CA-B5C2-D65B581AC718Q35569236-27C857EB-5E7B-4184-A916-E27EC846C957Q35846634-01A73FEA-3B73-4294-A1F8-30BABDDB1CC8Q35907004-0E0076B0-BE21-4C03-8C17-208E458810A3Q36076431-799CFBBB-8487-4EE0-9CD3-BA1C8C9AB31AQ36166928-B3ED836E-26E5-4AE5-A30F-FEF59119A9BAQ36338687-A2D0B1BD-E2E6-4D41-972A-32986215CCC7Q36414802-38DC3309-A799-4CD7-A735-190EC3610967Q36613697-E25FDB88-CF4E-449E-8B38-CDC69CB195CAQ36613702-E9F52770-344E-4766-B329-2B491D699127Q37017282-48B3B245-E203-43A5-A5A7-7DA58CC964D4Q37578986-1D271A3B-C986-44FF-9A18-5C4F2898102EQ38632663-35076372-A50F-40C7-9FE7-41B0CB2780B9Q38708006-E9B75F85-41BB-4E38-A7AD-ADCEB963392AQ40231112-15F801F9-A51D-4430-8E3F-82682A7874C0Q40238681-83535D1F-F169-4241-97DE-5AAB5ABA0964Q40336902-FF446A0D-EF1B-4AE4-8BF4-200EEA74EABDQ40467926-7967CED3-B95C-47E0-BB04-D8E91DD57D4AQ41993329-C81793D4-ED32-4908-AF8E-C5BD58E3C653Q46949685-7C7B9730-CA68-4B06-91C1-D198F8E8B222Q47432858-06085FE8-CFB5-440D-B44A-20964BF9A0F9Q47714049-DFD6ED84-DD48-4C6C-8EB4-79D3837C6A1DQ48102100-2E48E0D5-BE80-4B5F-BC55-52ABFE85C317Q48303531-CA1CE0BF-7B50-45BC-AB08-D5F50320A774Q50045324-878DC0FD-819E-498E-87B4-E038C3E50954Q50097601-131068EC-5B72-4B93-8DEA-7E2D285EAF60Q53682120-9218C965-9638-43A1-8699-78E72223D8BAQ55431612-1CBFF4AA-EE8A-4353-91EC-0365BEDD8E9CQ55432495-2538B07E-C080-4985-9BA0-E33BA36856FC
P2860
Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.
@en
Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.
@nl
type
label
Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.
@en
Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.
@nl
prefLabel
Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.
@en
Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.
@nl
P2093
P2860
P356
P1476
Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.
@en
P2093
Arun K Ghosh
David D Anderson
Hiroaki Mitsuya
Irene T Weber
P2860
P304
P356
10.1002/ANIE.201102762
P407
P577
2012-01-31T00:00:00Z